title: Immunomodulation by genetically engineered lactic acid bacteria.
abstract: The taxonomically diverse lactic acid bacteria (LAB) are unified by their capability to produce lactic acid from carbohydrates by fermentation. The LAB Lactococcus (L.) lactis has been characterized into great detail and is increasingly used as a production host for heterologous proteins. L. lactis is a non-pathogenic and non-colonizing LAB species and can be efficiently engineered to produce proteins of viral, bacterial or eukaryotic origin, both intra- or extracellularly. Importantly, orally formulated L. lactis strains (ActoBiotics), engineered to synthesize and secrete therapeutic peptides and proteins in the gastrointestinal tract, are already in advanced stages of preclinical and clinical development. This review focuses on the genetic engineering of LAB in general and L. lactis in specific to secrete high-quality, correctly processed, bioactive molecules derived from a eukaryotic background. The therapeutic applications of these genetically modified strains are discussed, as well as the need for a sound environmental containment strategy, and a detailed review is presented on Lactococcus strains engineered to produce specific antigens, antibodies, cytokines and trefoil factors, with special regards to immunomodulation.
authors.affiliation: ActoGeniX N.V., Technologiepark 4, 9052 Zwijnaarde, Belgium. Karolien.VanHuynegem@ActoGeniX.com
authors.forename: Karolien
authors.initials: K
authors.lastname: Van Huynegem
authors.forename: Michaela
authors.initials: M
authors.lastname: Loos
authors.forename: Lothar
authors.initials: L
authors.lastname: Steidler
mesh_terms: D000818:Animals; D000906:Antibodies / Q000235:genetics; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000096:biosynthesis / Q000235:genetics; D003264:Containment of Biohazards; D006801:Humans; D007155:Immunologic Factors / Q000096:biosynthesis* / Q000235:genetics*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy; D017045:Lactococcus / Q000235:genetics* / Q000276:immunology*; D013294:Lactococcus lactis / Q000235:genetics / Q000276:immunology; D019936:Probiotics / Q000627:therapeutic use; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics; D018417:Th1 Cells / Q000276:immunology; D014614:Vaccines, Synthetic / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000906:Antibodies; D001428:Bacterial Vaccines; D007155:Immunologic Factors; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic